Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Franklin Iheanacho, Medical student at Warren Alpert Medical School of Brown University, shared on LinkedIn:
“New paper alert! Published in American Cancer Society Cancer Journal.
From 2007-2017, sorafenib was the only systemic option for hepatocellular carcinoma. Post-2017, 9 new therapies emerged!
We studied:
– Treatment trends
– Survival shifts
Most importantly, this was the first registry study on how these therapies impact the U.S. population so far.
Summary:
Treatment trends:
Local therapies (ablation, EBRT, resection) stayed stable, with slight drops in embolization & transplant.
Systemic therapy shifted to novel options: lenvatinib, nivolumab, atezo/bev, pembrolizumab.
Median lines of treatment rose (slightly) from 1.2 to 1.4 (p=0.004).
Survival shifts:
Modest OS improvement over time for all patients.
Better survival for those starting with systemic therapy.
Decline in survival for those starting with local therapy.
This may indicate a shift in the patient populations receiving local versus systemic therapy first.
Big thanks to Angela T., Thomas A. M.D.Abrams, Dr. Manz and Dana-Farber Cancer Institute for guidance on this project.”
Authors: Franklin Iheanacho, Angela C. Tramontano, Thomas Adam Abrams, Christopher R. Manz
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023